José Luís Medina

José Luís Medina

Auto-generated profile, based on publicly available information

José Luís Medina

Porto University, Porto Medical School, Porto, Portugal

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2002 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
LML Van Maldergem
L Van Maldergem
JMJ Magré
J Magré
TKT E Khallouf
T E Khallouf
TGT Gedde-Dahl
T Gedde-Dahl
MDM Delépine
M Delépine
SOS O’rAhilly
S O’rAhilly
Generalised lipodystrophy of the Berardinelli-Seip type (BSCL) is a rare autosomal recessive human disorder with severe adverse metabolic consequences. A gene on chromosome 9 (BSCL1) has recently been identified, predominantly in African-American families. More recently, mutations in a previously undescribed gene of unknown function (BSCL2) on chromosome 11, termed seipin, have been found to be responsible for this disorder in a number of European and Middle Eastern families. We have studied the genotype/phenotype relationships in 70 affected subjects from 44 apparently unrelated pedigrees of diverse ethnic origin. In all subjects, hepatic dysfunction, hyperlipidaemia, diabetes mellitus, and hypertrophic cardiomyopathy were significant contributors to morbidity with no clear differences in their prevalence between subjects with BSCL1 or BSCL2 and those with evidence against cosegregation with either chromosome 9 or 11 (designated BSCLX). BSCL2 appears to be a more severe disorder than BSCL1 with a higher incidence of premature death and a lower prevalence of partial and/or delayed onset of lipodystrophy. Notably, subjects with BSCL2 had a significantly higher prevalence of intellectual impairment than those with BSCL1 or BSCLX (p<0.0001, OR 17.0, CI 3.6 to 79.0). The higher prevalence of intellectual impairment and the increased risk of premature death in BSCL2 compared to BSCL1 emphasise the importance of molecular diagnosis of this syndrome and have clear implications for genetic counselling.

1 June 2020 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MBMichael Bergman
Michael Bergman
MAMuhammad Abdul-Ghani
Muhammad Abdul-Ghani
RDRalph A. A. DeFronzo
Ralph A. A. DeFronzo
Manco MelaniaManco Melania
Manco Melania
GSGiorgio Sesti
Giorgio Sesti
MBMartin Buysschaert
Martin Buysschaert

8 October 2014 in Endocrine
Verified
Journal Article
Closed access
PDF file
MBMartin Buysschaert
Martin Buysschaert
JMJosé Luís Medina
José Luís Medina
MBMichael Bergman
Michael Bergman
ASAvni Shah
Avni Shah
JLJaqueline Lonier
Jaqueline Lonier

1 December 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MBMichael Bergman
Michael Bergman
Manco MelaniaManco Melania
Manco Melania
GSGiorgio Sesti
Giorgio Sesti
RDRachel Dankner
Rachel Dankner
MPManan Pareek
Manan Pareek
ACAntonio Ceriello
Antonio Ceriello

11 September 2015 in Current Diabetes Reviews
Verified
Journal Article
Closed access
MBMartin Buysschaert
Martin Buysschaert
JMJose-Luis Medina
Jose-Luis Medina
BBBenoit Buysschaert
Benoit Buysschaert
MBMichael Bergman
Michael Bergman
Diagnosis of type 2 diabetes and prediabetes is mandatory. Chronic hyperglycemia in diabetes is associated with long-term micro- and macrovascular as well as with neurological complications. Prediabetes predisposes patients to develop diabetes and macrovascular disease. Diagnosis of diabetes is established on (at least) one of the following criteria: a fasting plasma glucose ≥ 126 mg/dl (7.0 mmol/l), a casual plasma glucose ≥ 200 mg/dl (11.1 mmol/l) in the presence of symptoms, a 2-h plasma glucose during the 75-g oral glucose tolerance test (OGTT) ≥ 200 mg/dl (11.1 mmol/l) and/or an HbA1c ≥ 6.5%. Prediabetes is defined by the Position Statement of the American Diabetes Association as a fasting plasma glucose between 100 and 125 mg/dl (5.6 - 6.9 mmol/l) [a condition called Impaired Fasting Glucose] and/or by a 2-h plasma glucose during OGTT 140 - 199 mg/dl (7.8 - 11.0 mmol) [Impaired Glucose Tolerance] and/or a HbA1c level 5.7 - 6.4%, with however some potential discordance between tests. The threshold of fasting plasma glucose defining Impaired Fasting Glucose as well as the adequacy of HbA1c as a correct diagnostic tool for prediabetes is still debated.

1 April 2010 in Journal of Clinical Densitometry
Verified
Journal Article
Closed access
PFPaula Freitas
Paula Freitas
Ana SantosAna Santos
Ana Santos
DCDavide Carvalho
Davide Carvalho
JPJorge Pereira
Jorge Pereira
RMRui Marques
Rui Marques
JMJosé Luís Medina
José Luís Medina